NASDAQ:IRMD

IRadimed Stock Forecast, Price & News

$22.94

-0.17 (-0.74 %)

(As of 01/22/2021 12:00 AM ET)

Add

Compare

Today's Range

$22.56

Now: $22.94▼

$22.97

50-Day Range

$22.61

MA: $23.79▼

$25.00

52-Week Range

$14.41

Now: $22.94▼

$28.43

Volume17,800 shs

Average Volume17,521 shs

Market Capitalization$281.47 million

P/E Ratio71.69

Dividend YieldN/A

Beta1.16

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.

MarketRank^™

Overall MarketRank^™

1.69 out of 5 stars

Medical Sector

218th out of 1,923 stocks

Surgical & Medical Instruments Industry

20th out of 169 stocks

2.5 Analyst's Opinion

Consensus Rating
IRadimed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $26.00, IRadimed has a forecasted upside of 13.3% from its current price of $22.94.
Amount of Analyst Coverage
IRadimed has received no research coverage in the past 90 days.

2.4 Community Rank

Outperform Votes
IRadimed has received 227 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
IRadimed has received 253 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
IRadimed has received 52.71% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about IRadimed and other stocks. Vote “Outperform” if you believe IRMD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IRMD will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
IRadimed does not currently pay a dividend.
Dividend Growth
IRadimed does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, IRadimed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $48,551.00 in company stock.
Percentage Held by Insiders
50.90% of the stock of IRadimed is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
36.76% of the stock of IRadimed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9 Earnings and Valuation

Earnings Growth
Earnings for IRadimed are expected to grow by 150.00% in the coming year, from $0.12 to $0.30 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of IRadimed is 71.69, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.07.
Price to Earnings Ratio vs. Sector
The P/E ratio of IRadimed is 71.69, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 35.88.
Price to Book Value per Share Ratio
IRadimed has a P/B Ratio of 4.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Surgical & medical instruments

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:IRMD

Previous Symbol

CUSIPN/A

CIK1325618

Webwww.iradimed.com

Phone407-677-8022

Employees114

Debt

Debt-to-Equity RatioN/A

Current Ratio13.22

Quick Ratio12.25

Price-To-Earnings

Trailing P/E Ratio71.69

Forward P/E Ratio191.17

P/E GrowthN/A

Sales & Book Value

Annual Sales$38.52 million

Price / Sales7.31

Cash Flow$0.93 per share

Price / Cash Flow24.78

Book Value$4.83 per share

Price / Book4.75

Profitability

EPS (Most Recent Fiscal Year)$0.78

Net Income$9.63 million

Net Margins11.67%

Return on Equity6.83%

Return on Assets5.79%

Miscellaneous

Outstanding Shares12,270,000

Market Cap$281.47 million

Next Earnings Date2/4/2021 (Estimated)

OptionableNot Optionable

$22.94

-0.17 (-0.74 %)

(As of 01/22/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive IRMD News and Ratings via Email

Sign-up to receive the latest news and ratings for IRMD and its competitors with MarketBeat's FREE daily newsletter.

IRadimed (NASDAQ:IRMD) Frequently Asked Questions

How has IRadimed's stock been impacted by COVID-19?

IRadimed's stock was trading at $22.51 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, IRMD stock has increased by 1.9% and is now trading at $22.94.
View which stocks have been most impacted by COVID-19.

Is IRadimed a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IRadimed in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IRadimed stock.
View analyst ratings for IRadimed or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than IRadimed?

Wall Street analysts have given IRadimed a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but IRadimed wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is IRadimed's next earnings date?

IRadimed is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for IRadimed.

How were IRadimed's earnings last quarter?

IRadimed Co. (NASDAQ:IRMD) released its quarterly earnings data on Wednesday, November, 4th. The medical equipment provider reported $0.11 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.10 by $0.01. The medical equipment provider had revenue of $7.70 million for the quarter, compared to the consensus estimate of $7.46 million. IRadimed had a trailing twelve-month return on equity of 6.83% and a net margin of 11.67%.
View IRadimed's earnings history.

What price target have analysts set for IRMD?

1 brokers have issued 12-month price objectives for IRadimed's shares. Their forecasts range from $26.00 to $26.00. On average, they anticipate IRadimed's stock price to reach $26.00 in the next twelve months. This suggests a possible upside of 13.3% from the stock's current price.
View analysts' price targets for IRadimed or view Wall Street analyst' top-rated stocks.

Who are some of IRadimed's key competitors?

Some companies that are related to IRadimed include GenMark Diagnostics (GNMK), Tactile Systems Technology (TCMD), SI-BONE (SIBN), OraSure Technologies (OSUR), MiMedx Group (MDXG), CryoLife (CRY), LeMaitre Vascular (LMAT), Intersect ENT (XENT), OrthoPediatrics (KIDS), Orthofix Medical (OFIX), Vapotherm (VAPO), Antares Pharma (ATRS), Pulse Biosciences (PLSE), Acutus Medical (AFIB) and AngioDynamics (ANGO).
View all of IRMD's competitors.

What other stocks do shareholders of IRadimed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IRadimed investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Alphabet (GOOG), Mastercard (MA), Micron Technology (MU), PayPal (PYPL), CRISPR Therapeutics (CRSP), IntriCon (IIN), QUALCOMM (QCOM) and Twitter (TWTR).

Who are IRadimed's key executives?

IRadimed's management team includes the following people:

Mr. Roger E. Susi, Founder, Chairman, CEO & Pres (Age 68, Pay $488.45k)
Mr. Christopher K. Scott, CFO & Sec. (Age 51, Pay $337.77k)
Ms. Mary Beth Smith, VP of Sales
Mr. Matt Garner, Controller

What is IRadimed's stock symbol?

IRadimed trades on the NASDAQ under the ticker symbol "IRMD."

How do I buy shares of IRadimed?

Shares of IRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is IRadimed's stock price today?

One share of IRMD stock can currently be purchased for approximately $22.94.

How big of a company is IRadimed?

IRadimed has a market capitalization of $281.47 million and generates $38.52 million in revenue each year. The medical equipment provider earns $9.63 million in net income (profit) each year or $0.78 on an earnings per share basis. IRadimed employs 114 workers across the globe.

What is IRadimed's official website?

The official website for IRadimed is www.iradimed.com.

How can I contact IRadimed?

IRadimed's mailing address is 1025 Willa Springs Dr., Winter Springs FL, 32708. The medical equipment provider can be reached via phone at 407-677-8022 or via email at inves[email protected]

This page was last updated on 1/25/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here